Crossject
Develops emergency medications delivered via a needle-free auto-injector platform.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
Description
Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-09-13 18:28 |
CROSSJECT : Descriptif du programme de rachat
|
French | 59.9 KB | ||
| 2017-09-13 18:20 |
CROSSJECT : nb total de dts de vote et de capita
|
French | 56.3 KB | ||
| 2017-08-16 17:57 |
CROSSJECT : nombre total de droits de vote et d'actions
|
French | 57.4 KB | ||
| 2017-06-08 18:00 |
CROSSJECT : point d'activité
|
French | 72.7 KB | ||
| 2017-06-08 18:00 |
CROSSJECT : nombre total de droits de vote et d'actions
|
French | 57.3 KB | ||
| 2017-05-19 18:00 |
CROSSJECT: Résultats des votes de l'AG du 17 mai 2017
|
French | 352.9 KB | ||
| 2017-05-09 18:00 |
CROSSJECT : nb total de droits de vote et d'actions
|
French | 77.3 KB | ||
| 2017-05-05 19:11 |
CROSSJECT: mise à disposition du rapport annuel 2016
|
French | 77.9 KB | ||
| 2017-04-13 08:31 |
CP CROSSJECT inaugure une unité de production.
|
French | 172.4 KB | ||
| 2017-04-05 17:46 |
CP CROSSJECT : Large succès de l'augmentation de capital Crossject.
|
French | 462.9 KB | ||
| 2017-03-16 18:00 |
CP CROSSJECT reçoit le paiement de 2,9 M€ alloué par Bpifrance.
|
French | 170.9 KB | ||
| 2017-03-09 18:39 |
CP CROSSJECT : Lancement d'une AK avec maintien du DPS pour 4,3 M€.
|
French | 584.5 KB | ||
| 2017-03-09 17:45 |
CP CROSSJECT : Nombre total de droits de vote et d'actions au 28.02.17
|
French | 506.3 KB | ||
| 2017-03-06 07:00 |
CP CROSSJECT : Autorisation étude de bioéquivalence Zeneo Midazolam.
|
French | 267.5 KB | ||
| 2017-02-21 11:08 |
CP CROSSJECT : Nombre total de droits de vote et d'actions au 31.01.17
|
French | 505.1 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crossject
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
Peer Companies
